Teva (NYSE: TEVA) officer sells 14,150 shares under 10b5-1 plan

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD officer Jover Placid reported restricted share units vesting and related share sales. On March 5, 2026, 14,150 restricted share units were exercised into 14,150 ordinary shares at $0.0000 per share.

The same day, he sold 14,150 ordinary shares at a weighted average price of $31.6684 per share in open-market transactions under a Rule 10b5-1 trading plan adopted on November 10, 2025. The sale included shares to cover tax withholding on vesting. Following these transactions, he directly holds 6,774 ordinary shares and 42,453 restricted share units.

Insider Trade Summary

Net Seller: 14,150 shares ($448,108)

Net Sell 3 txns

Insider Jover Placid

Role See "Remarks"

Sold 14,150 shs ($448K)

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	14,150	$0.00	--
Exercise	Ordinary Shares	14,150	$0.00	--
Sale	Ordinary Shares	14,150	$31.6684	$448K

Holdings After Transaction: Restricted Share Units — 42,453 shares (Direct); Ordinary Shares — 20,924 shares (Direct)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on March 5, 2025, with 14,150 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 14,153 vesting on March 5, 2029.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jover Placid

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See "Remarks"

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/05/2026		M		14,150	A	(2)	20,924	D
Ordinary Shares(1)	03/05/2026		S(3)		14,150(4)	D	$31.6684(5)	6,774	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/05/2026		M			14,150	(6)	(6)	Ordinary Shares(1)	14,150	$0	42,453	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

4. Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. Restricted share units were granted on March 5, 2025, with 14,150 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 14,153 vesting on March 5, 2029.

Remarks:

Executive Vice President, Chief Human Resources Officer

	/s/ Dov Bergwerk as attorney-in-fact for Placid Jover	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Jover Placid report for TEVA on March 5, 2026?

Jover Placid reported RSU vesting and a matching share sale. 14,150 restricted share units converted into 14,150 ordinary shares, and all 14,150 shares were then sold the same day in open-market transactions linked to the vesting event.

How many Teva (TEVA) shares did Jover Placid sell and at what price?

He sold 14,150 Teva ordinary shares. The weighted average sale price was $31.6684 per share, with individual trades executed in a price range from $31.26 to $32.34, according to the reported transaction details and accompanying footnote.

Were Jover Placid’s TEVA share sales executed under a Rule 10b5-1 trading plan?

Yes, the sale was made under a Rule 10b5-1 trading plan. The plan was adopted by the reporting person on November 10, 2025, and governed the March 5, 2026 transactions disclosed in the filing, according to the stated footnote explanation.

How many Teva (TEVA) shares and RSUs does Jover Placid hold after these transactions?

After the reported transactions, he directly holds 6,774 ordinary shares and 42,453 restricted share units. These figures reflect the RSU vesting, the exercise into ordinary shares, and the subsequent sale of 14,150 ordinary shares described in the insider report.

What are the terms of the restricted share units reported by Jover Placid at TEVA?

Each restricted share unit represents a contingent right to receive one ordinary share or, at committee discretion, its cash value. A grant made March 5, 2025 vests 14,150 units annually on March 5, 2026, 2027, 2028 and 14,153 units on March 5, 2029.

Did the TEVA insider sale include shares used to cover tax withholding obligations?

Yes, the sale covered all shares that vested in the transaction. The filing states the reporting person sold all vested shares, including those required to satisfy tax withholding obligations arising from the vesting of the restricted share units.